Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: LGND stock price vs CW: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CW's multiple
Needs CW P/E.
Implied fair value · at LGND's multiple
Needs LGND P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · CW FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Bear
$101.45
Base
$119.35
Bull
$137.25
CURTISS-WRIGHT CORPORATION · implied price per share
Bear
$116.65
Base
$137.24
Bull
$157.83
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.25x
0.46x
Net debt / EBITDA
Leverage against operating earnings
-2.31x
1.24x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$171.00M
Total debt
Interest-bearing obligations outstanding
$252.03M
$1.16B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe LGND's high revenue growth and superior margin profile can persist while its weaker quality signals do not deteriorate, then a selective long position is reasonable because the P/E-based comparison still implies 13.3% upside versus CW and LGND carries lighter leverage.
On the provided P/E comparison, LGND's implied price of $362.10 is 13.3% above the current price of $319.55, suggesting modest upside versus CW-based valuation. However, CW implied range is wide and the DCF range of $80.49 to $108.90 is dramatically below both current price and the P/E-implied value, which makes the valuation signal less definitive.
Supporting Metrics
